Drugs / nicotinamide mononucleotide
nicotinamide mononucleotide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05984550 | Aug 2023 → Mar 2024 | — | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07572825 | May 2026 → Aug 2027 expected | DHDDS-CDG, congenital disorder of glycosylation | Eva Morava-Kozicz | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06776510 | Jan → Dec 2025 overdue | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07013591 | Jun 2026 → Oct 2028 expected | — | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06882096 Comparator | Apr 2025 → Dec 2026 expected | — | Metro International Biotech, LLC | Recruiting | No outcome recorded |
| — | NCT04823260 Comparator | May → Sep 2021 | — | Abinopharm, Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotinamide mononucleotide | “NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide.” NCT05984550 ↗5“oral nicotinamide mononucleotide (NMN) administration” NCT07013591 ↗ |
| Known as | MIB-626 | “NMN (MIB-626) 1000 mg PO daily, for 7 days preoperatively, on day of surgery, and for 3 days postoperatively” NCT07013591 ↗ |
| Known as | NMN | “The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol...” NCT07572825 ↗4“nicotinamide mononucleotide (NMN) has been explored in clinical trials” NCT06776510 ↗ “oral nicotinamide mononucleotide (NMN) administration” NCT07013591 ↗ “Nicotinamide Mononucleotide (NMN)” NCT06882096 ↗ |
| Action | Restore | “CD38 inhibition or nicotinamide mononucleotide (NMN) supplementation restores NAD+” PMID 42056497 ↗ Apr 2026 |
| Modality | Other / unclassified | “NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide” NCT05984550 ↗ |
| Route | Oral | “oral dosing up to 900 mg NMN daily” PMID 36482258 ↗ Dec 2022 |